GSK plans new flagship R&D centre on Cambridge Biomedical Campus
The £400 million investment will house over 1,000 scientists and accelerate R&D.
See the latest news and media coverage for GSK. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global biopharmaceutical company
gsk.comLast updated
In short: GSK completed its $10.6 billion acquisition of Nuvalent and secured FDA approval for Jideytro, expanding its oncology and lung cancer portfolio.
The £400 million investment will house over 1,000 scientists and accelerate R&D.
The ARTEMIS-011 trial met its primary endpoint of progression-free survival in relapsed osteosarcoma.
The approval is based on the ARROS-1 trial demonstrating durable responses in previously treated patients.
The presentations include phase IIIb VOGUE study comparing Dovato with Biktarvy and long-acting injectable data.
July 30 (Reuters) - British biotech firm Relation Therapeutics said on Wednesday it had entered into a research collaboration with GSK (GSK.L), opens new tab...
GSK's licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China: London, UK GSK plc licensor...
GSK, led by boss Luke Miels, pictured, said it will be closing down its R&D site in Stevenage, Hertfordshire, and moving its staff to a...
GSK Plc GSK stock rose Tuesday after the British drugmaker reported better-than-expected second-quarter results. Launches ...
Track GSK and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to GSK and other trending companies.